Evidence for association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome in south-west Chinese women

European Journal of Endocrinology

Volumn 166, Issue 5, 2012, Pages 877-885

  Wang, Ying ^a   Liu, Hongwei ^a   Fan, Ping ^a   Bai, Huai ^a   Zhang, Jinxia ^a   Zhang, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEUCINE; LOW DENSITY LIPOPROTEIN; METHIONINE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PARAOXONASE 1 GENE; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADOLESCENT; ADULT; ARGININE; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GLUTAMINE; HUMANS; LEUCINE; METHIONINE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84862111630     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0986     Document Type: Article

References (42)

1. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Seminars in Reproductive Medicine 2008 26 39-44. (doi:10.1055/s-2007- 992923)
2. Dhindsa G, Bhatia R, Dhindsa M & Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. Journal of Postgraduate Medicine 2004 50 140-144. (Pubitemid 39069772)
3. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-25. (doi:10.1016/fertnstert.2003.10.004)
4. Moran L & Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Update 2009 15 477-488. (doi:10.1093/humupd/dmp008)
5. Gonzalez F, Rote NS, Minium J & Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 336-340. (doi:10.1210/jc.2005-1696)
6. Repaci A, Gambineri A & Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Molecular and Cellular Endocrinology 2011 335 30-41. (doi:10.1016/j.mce.2010.08.002)
7. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W & Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. (doi:10.1210/jc.2007-0425)
8. Ovalle F & Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and Sterility 2002 77 1095-1105. (doi:10.1016/S0015-0282(02)03111-4)
9. Goodarzi MO. Looking for polycystic ovary syndrome genes: rational and best strategy. Seminars in Reproductive Medicine 2008 26 5-13. (doi:10.1055/s-2007-992919)
10. Escobar-Morreale HF, Luque-Ramirez M & San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 2005 26 251-282. (doi:10.1210/er.2004-0004)
11. Camps J, Marsillach J & Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences 2009 46 83-106. (doi:10.1080/10408360802610878)
12. Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E & Levy E. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011 214 20-36. (doi:10.1016/j.atherosclerosis.2010.08.076)
13. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ & Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research 2004 45 993-1007. (doi:10.1194/jlr.R400001-JLR200)
14. Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, Vandeberg JL, Almasy L, Blangero J, Maccluer JW & Mahaney MC. Determinants of variation in human serum paraoxonase activity. Heredity 2009 102 147-154. (doi:10.1038/hdy.2008.110)
15. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J & Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics 1996 14 334-336. (doi:10.1038/ng1196- 334)
16. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ & Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993 3 73-76. (doi:10.1038/ng0193-73)
17. Mackness B, Durrington PN & Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999 353 468-469. (doi:10.1016/S0140-6736(98)05105-8)
18. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP & Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics 2001 68 1428-1436. (doi:10.1086/320600)
19. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ & Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Journal of the American Medical Association 2008 299 1265-1276. (doi:10.1001/jama.299.11.1265)
20. Wang M, Lang X, Zou L, Huang S & Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 2011 214 377-385. (doi:10.1016/j. atherosclerosis.2010.11.028)
21. Can Demirdogen B, Turkanoglu A, Bek S, Sanisoglu Y, Demirkaya S, Vural O, Arinc E & Adali O. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphismand PON1 status are associated with increased risk of ischemic stroke. Clinical Biochemistry 2008 41 1-9. (doi:10.1016/j.clinbiochem.2007.08. 010)
22. Ichikawa K, Konta T, Emi M, Toriyama S, Takasaki S, Ikeda A, Shibata Y, Takabatake N, Takeishi Y, Kato T, Kawata S & Kubota I. Genetic polymorphisms of paraoxonase-1 are associated with chronic kidney disease in Japanese women. Kidney International 2009 76 183-189. (doi:10.1038/ki.2009.97)
23. Zintzaras E & Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a metaanalysis. Journal of Human Genetics 2004 49 474-481. (doi:10.1007/s10038-004-0176-x)
24. Leviev I, Kalix B, Brulhart Meynet MC & James RW. The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia 2001 44 1177-1183. (doi:10.1007/s001250100610)
25. Evans JL, Maddux BA & Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxidants & Redox Signaling 2005 7 1040-1052. (doi:10.1089/ars.2005.7.1040)
26. Dursun P, Demirtas E, Bayrak A & Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Human Reproduction 2006 21 104-108. (doi:10.1093/humrep/dei284)
27. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B & Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. Journal of Clinical Endocrinology and Metabolism 2004 89 2640-2646. (doi:10.1210/jc.2003-031252)
28. Zhang F, Liu HW, Fan P, Bai H & Song Q. The K108 C/T polymorphism in paraoxonase 1 gene in Chinese patients with polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban 2011 42 24-28.
29. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Li Z, You L, Zhao J, Liu J, Liang X, Zhao X, Sun Y, Zhang B, Jiang H, Zhao D, Bian Y, Gao X, Geng L, Li Y, Zhu D, Sun X, Xu JE, Hao C, Ren CE, Zhang Y, Chen S, ZhangW, Yang A, Yan J, Ma J & Zhao Y. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nature Genetics 2011 43 55-59. (doi:10.1038/ng.732)
30. Ginsberg G, Neafsey P, Hattis D, Guyton KZ, Johns DO & Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): population distribution of PON1 activity. Journal of Toxicology and Environmental Health. Part B, Critical Reviews 2009 12 473-507. (doi:10.1080/10937400903158409)
31. Guo M, Chen ZJ, Macklon NS, Shi YH, Westerveld HE, Eijkemans MJ, Fauser BC & Goverde AJ. Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. Reproductive Biomedicine Online 2010 21 572-580. (doi:10.1016/j.rbmo.2010.04. 032)
32. Fan P, Liu HW, Wang XS, Zhang F, Song Q, Li Q, Wu HM & Bai H. Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Human Reproduction 2010 25 1288-1294. (doi:10.1093/humrep/deq047)
33. Erlich HA. PCR technology: principles and applications for DNA amplification, 1st edn. New York: Stockton Press, 1989.
34. Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, Roots I & Stangl K. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999 9 755-761. (doi:10.1097/00008571-199912000-00010)
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
36. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E & Hasanoglu A. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clinical Endocrinology 2007 67 129-134. (doi:10.1111/j.1365-2265.2007.02849.x)
37. Fan P, Liu HW,Wan DH, Li Y, Song Q & Bai H. Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. Fertility and Sterility 2009 92 2054-2057. (doi:10.1016/j.fertnstert. 2009.06.022)
38. Fan P, Liu HW, Wang Y, Zhang F & Bai H. Apolipoprotein E-containing high-density lipoprotein-associated platelet-activating factor-acetylhydrolase activities and malondialdehyde levels in patients with PCOS. Reproductive BioMedicine Online 2012 24 197-205. (doi:10.1016/j.rbmo.2011.10.010)
39. Leviev I & James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 516-521. (doi:10.1161/01.ATV.20.2.516)
40. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P & Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation 1997 99 62-66. (doi:10.1172/JCI119134)
41. Mackness B, Mackness MI, Arrol S, Turkie W & Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters 1998 423 57-60. (doi:10.1016/S0014-5793(98)00064-7)
42. Camps J, Marsillach J & Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Reviews in Medicinal Chemistry 2009 9 911-920.